SHERRI ASBEL: Open Payments
NPI 1073047643 · ROME, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$853 in 46 payments from 14 companies in 2025. Trend: 2023 $329 · 2024 $245 · 2025 $853
Food & beverage: $853
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $224 |
| Janssen Biotech, Inc. | 5 | $97 |
| GENZYME CORPORATION | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| Madrigal Pharmaceuticals | 3 | $71 |
| Ipsen Biopharmaceuticals, Inc | 3 | $63 |
| Gilead Sciences, Inc. | 3 | $58 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $49 |
| Intercept Pharmaceuticals, Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
Products named: DUPIXENT, CREON, TREMFYA, ENTYVIO, REZDIFFRA, IQIRVO, MAVYRET, XIFAXAN.
Industry payments across GA — which companies pay providers there.
